The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1335
Plerixafor (Mozobil)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved plerixafor (Mozobil – Genzyme), a CXCR4 chemokine receptor antagonist, for use in combination with granulocyte-colony stimulating factor (G-CSF; Neupogen) to mobilize peripheral blood stem cells in adults with multiple myeloma or non-Hodgkin’s lymphoma before high-dose chemotherapy with autologous stem cell rescue.

STANDARD TREATMENT — High-dose chemotherapy can overcome mechanisms of resistance to conventional chemotherapy, increasing survival rates of multiple myeloma and possibly curing some subtypes of non-Hodgkin’s lymphoma. G-CSF is the agent most commonly used to mobilize peripheral blood stem cells for harvest in preparation for high-dose chemotherapy, but some patients with non-Hodgkin’s lymphoma or multiple myeloma fail to mobilize a sufficient number of cells with G-CSF alone.1

MECHANISM OF ACTION — Plerixafor is ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Plerixafor (Mozobil)
Article code: 1335b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian